Ipswich Investment Management Co. Inc. Sells 2,601 Shares of Pfizer Inc. (NYSE:PFE)

by · The Cerbat Gem

Ipswich Investment Management Co. Inc. reduced its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 10.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,841 shares of the biopharmaceutical company’s stock after selling 2,601 shares during the period. Ipswich Investment Management Co. Inc.’s holdings in Pfizer were worth $658,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Front Street Capital Management Inc. lifted its holdings in Pfizer by 4.3% during the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock worth $268,000 after purchasing an additional 215 shares in the last quarter. Castleview Partners LLC lifted its holdings in shares of Pfizer by 2.4% in the first quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 287 shares in the last quarter. United Bank boosted its position in shares of Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after acquiring an additional 290 shares during the period. Compton Capital Management Inc. RI grew its stake in Pfizer by 0.5% during the first quarter. Compton Capital Management Inc. RI now owns 63,891 shares of the biopharmaceutical company’s stock valued at $3,308,000 after acquiring an additional 300 shares in the last quarter. Finally, GHP Investment Advisors Inc. lifted its stake in Pfizer by 2.4% in the 4th quarter. GHP Investment Advisors Inc. now owns 13,332 shares of the biopharmaceutical company’s stock worth $683,000 after purchasing an additional 307 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

NYSE PFE opened at $26.00 on Friday. The company has a 50-day simple moving average of $27.11 and a two-hundred day simple moving average of $28.65. Pfizer Inc. has a 12-month low of $25.23 and a 12-month high of $40.37. The firm has a market cap of $147.23 billion, a price-to-earnings ratio of 72.22, a PEG ratio of 1.17 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the previous year, the company posted $1.14 EPS. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. On average, equities analysts forecast that Pfizer Inc. will post 2.24 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PFE. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Guggenheim started coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Twelve research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $36.88.

Read Our Latest Stock Report on Pfizer

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).